Next-Generation Sequencing Services Market to Reach USD 8.77 Billion by 2030

Next-Generation Sequencing (NGS) Services Market by Type (Targeted, RNA-Seq, Exome, De Novo), Technology (Sequencing by Synthesis, Ion semiconductor, SMRT, Nanopore), & Application (Diagnostics, Oncology, Drug Discovery, Agriculture) - Global Forecast to 2030
The global next-generation sequencing (NGS) services market is entering a period of accelerated expansion, projected to grow from USD 3.80 billion in 2025 to USD 8.77 billion by 2030, registering a robust Compound Annual Growth Rate (CAGR) of 18.2%.

What is fueling this rapid growth? Why are healthcare systems, biopharma companies, and research institutions increasing investments in outsourced sequencing services? And how is the evolution of clinical genomics reshaping long-term market opportunity?

The answer lies in the convergence of rising cancer incidence, expanding rare-disease programs, declining sequencing costs, and the institutionalization of genomics within mainstream healthcare and drug development.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194102241 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194102241&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Structural Growth Drivers: Oncology, Rare Disease, and Population Genomics

Multiple factors are driving sustained growth in the global next-generation sequencing services market.

The rising global cancer burden and the expansion of rare-disease testing programs are significantly increasing demand for rapid, report-ready sequencing services in both routine clinical and translational research settings. Comprehensive genomic profiling (CGP), tumor sequencing, and hereditary disease panels are becoming standard components of precision medicine workflows.

At the same time, sequencing costs have declined substantially, enabling larger-scale studies and higher clinical testing volumes. This cost-efficiency is strengthening the business case for integrating NGS into standard diagnostic pathways and biopharmaceutical research pipelines.

In parallel, population genomics initiatives and national genomics programs are expanding across multiple regions. These initiatives are creating steady, recurring project flows for outsourced sequencing, bioinformatics analysis, and long-term data management-transforming NGS services from episodic projects into scalable infrastructure contracts.

For C-suite executives and strategy leaders, the NGS services market represents a critical enabler of precision medicine, targeted therapeutics, and data-driven healthcare delivery.

Sequencing Services Maintain Dominant Share

By service type, the market is segmented into sequencing services, pre-sequencing services, bioinformatics services, and NGS platform services.

In 2024, sequencing services accounted for the dominant market share. This leadership is largely volume-driven, as service providers manage high-throughput projects across oncology, rare disease diagnostics, reproductive health, and infectious disease surveillance.

Why does sequencing remain central? High sample volumes and the operational complexity of large-scale genomic studies continue to drive outsourcing demand. Academic institutions, pharmaceutical companies, and clinical laboratories increasingly rely on specialized providers to ensure speed, accuracy, and regulatory alignment.

Diagnostics Segment to Lead Growth Through 2030

By application, the next-generation sequencing services market includes diagnostics, drug discovery and development, agriculture & animal research, and other applications.

The diagnostics segment is estimated to remain the largest and register the highest CAGR from 2025 to 2030. In 2024, diagnostics dominated the market due to heavy testing demand across oncology, hereditary diseases, and infectious disease workflows.

Routine tumor profiling, comprehensive genomic profiling (CGP), and the steady rise of companion diagnostics linked to targeted therapies are accelerating clinical adoption. As precision oncology expands and regulatory approvals for targeted treatments increase, demand for reliable, high-throughput NGS services is expected to grow in parallel.

For pharmaceutical and biotech leaders, this trend underscores the strategic importance of integrating genomic testing into drug development, commercialization, and lifecycle management strategies.

Asia Pacific Positioned as the Fastest-Growing Regional Market

Asia Pacific is projected to be the fastest-growing region in the global NGS services market during the forecast period.

Within the region, China is emerging as a primary growth engine. Expansion is driven by high clinical testing volumes, a strong network of large hospitals and reference laboratories, and rapid scaling of outsourced sequencing for oncology, rare diseases, and infectious disease surveillance.

Additionally, increasing investments in biopharmaceutical R&D and trial genomics are generating repeat demand for sequencing and downstream data analysis services. As regional healthcare infrastructure and regulatory frameworks mature, Asia Pacific is expected to become a critical hub for genomic services expansion.

Request For Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=194102241 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=194102241&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Competitive Landscape

The NGS services market is characterized by the presence of established life sciences and genomic technology leaders offering integrated sequencing and analytical capabilities.

Prominent players operating in the NGS services market include Illumina, Inc. (US), Thermo Fisher Scientific (US), and Eurofins Scientific (Luxembourg), among others.

Strategic Implications for Industry Leaders

Why does this market matter now?

As healthcare systems transition toward precision medicine and data-driven decision-making, next-generation sequencing services are becoming foundational infrastructure rather than discretionary research tools.

For pharmaceutical companies, NGS supports target identification, biomarker discovery, clinical trial stratification, and companion diagnostic development. For healthcare providers, it enables earlier detection, improved treatment matching, and scalable genomic screening programs.

With an anticipated CAGR of 18.2% through 2030, the NGS services market represents a high-growth strategic domain where technology innovation, clinical demand, and policy support are converging.

Organizations that invest early in scalable sequencing capacity, advanced bioinformatics, and cross-border genomic collaborations will be best positioned to capture long-term value in the evolving precision medicine ecosystem.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nextgeneration-sequencing-services-market-to-reach-usd-877-billion-by-2030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ngs-services-market-194102241.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.